Suggested remit - To appraise the clinical and cost effectiveness of ozanimod within its marketing authorisation for treating relapsing multiple sclerosis.
Status In progress
Process STA 2018
ID number 1294

Provisional Schedule

Committee meeting: 1 13 May 2020
Expected publication 22 July 2020

Project Team

Project lead Jo Ekeledo

Email enquiries

Evidence Review Group / Assessment Group Liverpool Reviews and Implementation Group, University of Liverpool


Companies sponsors Celgene (ozanimod)
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Multiple Sclerosis Society
  Multiple Sclerosis Trust
Professional groups Association of British Neurologists
  UK Multiple Sclerosis Specialist Nurse Association
  Royal College of Physicians


Comparator companies Bayer (interferon beta-1b) (confidentiality agreement not signed, not participating)
  Biogen Idec (dimethyl fumarate, interferon beta-1a, natalizumab, peginterferon beta-1a)
  Genzyme Therapeutics (alemtuzumab, teriflunomide) (confidentiality agreement not signed, not participating)
  Merck Serono (cladribine tablets, interferon beta-1a) (confidentiality agreement not signed, not participating)
  Novartis (fingolimod, interferon beta-1b)
  Teva UK (glatiramer acetate) (confidentiality agreement not signed, not participating)
  Roche (ocrelizumab)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee


Key events during the development of the guidance:

Date Update
02 September 2019 Invitation to participate
30 August 2019 In progress, In progress
30 January 2018 - 27 February 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance